Henrik Grönberg, professor in cancer epidemiology at Karolinska Institutet (KI), receives a SEK 95 million grant from the Swedish Research Council to form a competence center at KI focusing on research on improved prostate and breast cancer diagnostics.
Literature search to identify the most promising clinical data and biomarkers to predict aggressive prostate cancer is carried out.
The STHLM2 study, a retrospective analysis on biomarkers, genetic markers and clinical data is carried out on a cohort of 25,000 men that took a PSA-test in 2011.
The pivotal prospective study STHLM3 is undertaken in close collaboration with the Stockholm Health Care Region. Nearly 60, 000 men aged 50 to 70 participate in the study that is carried out between 2012 and 2015.
The results from the STHLM3 study are published in The Lancet Oncology.
The STHLM3 study results in a blood test, now named Stockholm3.
The team behind Stockholm3 receive an EIT Health grant of SEK 17 million to accelerate European uptake.
Clinical validation studies on Stockholm3 on more than 20,000 men in Sweden, Norway, Germany, Holland and the United Kingdom are carried out between 2016 and 2019.
Stockholm3 wins the EIT Innovators Award. The award is given to teams that have developed a product, service or a process with a high potential for individuals and European society.
Stockholm3 is provided as Lab developed test (LDT) for clinical use.
Capio S:t Göran Hospital is the first healthcare provider in Sweden to completely replace PSA testing with Stockholm3.
A health economy study in Sweden shows that the Stockholm3 test saves approximately 17 percent in direct health care costs.
The regional care program group for prostate cancer in the Stockholm Region, consisting of the leading experts in the profession, recommends Stockholm3.
Approximately 20,000 Stockholm3 tests are taken in clinical practice in Sweden and Norway.
The team behind Stockholm3 win an EIT Health grant of SEK 27 million to validate a new blood test for men with metastatic prostate cancer in the OncoWatch project.
The team behind Stockholm3 is awarded SEK 23 million by Nordforsk to accelerate Nordic uptake.
Stavanger University Hospital is the first healthcare provider in Norway to completely replace PSA testing with Stockholm3.
A contract is signed with SYNLAB, Europe’s largest laboratory chain, to provide Stockholm3.
Pilot studies with leading healthcare providers in Denmark and Finland are initiated for Stockholm3.
A3P Biomedical AB is founded.
A health economy study in Norway shows that Stockholm3 can reduce the direct health care costs by 23 to 28 percent.
A3P Biomedical raises SEK 110 million in growth capital.
Stockholm3 wins first prize at the European Association of Urology.
An independent study shows the health economics advantages of Stockholm3 compared with PSA testing in general screening for prostate cancer.
Fast-track publication of the STHLM3 MR study in The Lancet Oncology shows that Stockholm3 in combination with MRI examinations facilitate a 76 percent reduction in the number of unnecessary biopsies in general screening for prostate cancer compared with the standard PSA test.
The Martini-Klinik, Europe’s largest prostate cancer clinic, begins using Stockholm3.
Stockholm3 developer Henrik Grönberg is named Cancer Researcher of the Year in Sweden.
An analysis in European Urology shows that Stockholm3 is cost-effective for general screening.
A3P Biomedical successfully completes a Private Placement of SEK 400 million.
Region Värmland introduces Stockholm3 in its organized program for prostate cancer screening.
Stockholm3 study is named the best scientific publication by the European Association of Urology.
Stockholm3 is included in the Swedish national guidelines for prostate cancer.
A3P Biomedical establishes a European sales organization.
Stockholm3 is introduced in Switzerland.
Stockholm3 is introduced in the United Kingdom.